60 Degrees Pharmaceuticals, Inc. (SXTP) Price & Analysis

Compare

189 Followers

SXTP Stock Chart & Stats

$0.50

-$0.08(-5.71%)

At close: Jan 08 4:00 PM EST

$0.50

-$0.08(-5.71%)

Day’s Range― - ―

52-Week Range$0.45 - $8.00

Previous CloseN/A

Volume13.44M

Average Volume (3M)199.18K

Market Cap

$2.17M

Enterprise Value$11.16M

Total Cash (Recent Filing)$4.12M

Total Debt (Recent Filing)$153.76K

Price to Earnings (P/E)―

Beta2.14

Next Earnings

Mar 27, 2026

EPS Estimate

-0.57

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.67

Shares Outstanding4,230,448

10 Day Avg. Volume488,900

30 Day Avg. Volume199,179

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.73

Price to Sales (P/S)4.83

P/FCF Ratio-0.50

Enterprise Value/Market Cap5.15

Enterprise Value/Revenue11.59

Enterprise Value/Gross Profit60.52

Enterprise Value/Ebitda-1.41

Forecast

1Y Price Target

$4.40

Price Target Upside780.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceProduct revenues showed a significant year-over-year increase, despite being supply-constrained.

Market OpportunitiesThe company survey indicates that Babesiosis prevalence could be significantly higher than CDC estimates, suggesting a larger potential market for Tafenoquine.

Sales GrowthArakoda sales continue to grow, with net product revenues reaching $607,574 in FY24, a significant increase from $253,573 in FY23.

Bears Say

EarningsQ1 earnings per share were below estimates due to higher than forecast SG&A expenses.

Supply ConstraintsProduct revenues showed a significant year-over-year increase, despite being supply-constrained.

60 Degrees Pharmaceuticals, Inc. News

60 Degrees announces detection of babesia infection in 24% of patients in study

60 Degrees Pharmaceuticals (SXTP) announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called...

14d ago

SXTP

60 Degrees Pharma outlines growth strategy in investor webinar

An announcement from 60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) is now available. On January 8, 2026, 60...

4d ago

SXTP

60 Degrees Pharmaceuticals expanding Arakoda sales and marketing in 2026

60 Degrees Pharmaceuticals (SXTP) announced the planned expansion of the company’s sales and marketing initiatives after encouraging results...

1M ago

SXTP

60 Degrees announces central site for B-FREE study open for patient enrollment

60 Degrees Pharmaceuticals (SXTP) announced that the central study site for the Company’s B-FREE Chronic Babesiosis Study, the...

2M ago

SXTP

60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth Efforts

60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) has released its Q3 earnings. Here is a breakdown of the...

2M ago

SXTP

60 Degrees Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of 60 Degrees Pharmaceuticals (SXTP) with a Buy rating and $6 price target The...

2M ago

SXTP

60 Degrees Pharmaceuticals reports Q3 EPS (66c) vs. ($4.65) last year

Q3 2025 net product revenue increased 223% year-over-year to $438,000. The company posted a gross loss of approximately...

2M ago

SXTP

SXTP Upcoming Earnings Report: What to Expect?

60 Degrees Pharmaceuticals, Inc. (SXTP) is scheduled to report 3rd quarter earnings on 11/13/2025. Regarding Q3 estimates, Wall...

2M ago

SXTP

60 Degrees Pharmaceuticals Advances Tafenoquine Study for Chronic Babesiosis

60 Degrees Pharmaceuticals, Inc. (($SXTP)) announced an update on their ongoing clinical study. Study Overview: The B-FREE Chronic...

3M ago

SXTP

60 Degrees announces first patient completed regimen in babesiosis trial

60 Degrees Pharmaceuticals (SXTP) announced that the first patient to have completed the regimen in the Company’s trial...

3M ago

SXTP

60 Degrees Pharmaceuticals Holds Annual Stockholders Meeting

60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) has provided an update. On October 8, 2025, 60 Degrees Pharmaceuticals,...

3M ago

SXTP

60 Degrees Pharmaceuticals unveils name of chronic babesiosis trial

60 Degrees Pharmaceuticals (SXTP) announced the name of its chronic babesiosis trial is the B-FREE Chronic Babesiosis Study....

3M ago

SXTP

60 Degrees Pharmaceuticals Highlights ARAKODA Growth Potential

An update from 60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) is now available. On September 9, 2025, 60...

4M ago

SXTP

60 Degrees Pharmaceuticals Enters New Sales Agreement

The latest update is out from 60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ). On September 3, 2025, 60...

4M ago

SXTP

SXTP FAQ

What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?

60 Degrees Pharmaceuticals, Inc. lowest stock price was $0.45 and its highest was $8.00 in the past 12 months.

What is 60 Degrees Pharmaceuticals, Inc.’s market cap?

60 Degrees Pharmaceuticals, Inc.’s market cap is $2.17M.

When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?

60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is Mar 27, 2026 which is in 74 days.

How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?

60 Degrees Pharmaceuticals, Inc. released its earnings results on Nov 13, 2025. The company reported -$0.665 earnings per share for the quarter, missing the consensus estimate of -$0.46 by -$0.205.

Is 60 Degrees Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does 60 Degrees Pharmaceuticals, Inc. pay dividends?

60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.

What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?

60 Degrees Pharmaceuticals, Inc.’s EPS estimate is -0.57.

How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?

60 Degrees Pharmaceuticals, Inc. has 4,230,448 shares outstanding.

What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?

60 Degrees Pharmaceuticals, Inc. reported an EPS of -$0.665 in its last earnings report, missing expectations of -$0.46. Following the earnings report the stock price went down -4.878%.

Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in SXTP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

60 Degrees Pharmaceuticals, Inc. (SXTP) Earnings & Revenues

Historic Earnings Reports

SXTP Stock 12 Month Forecast

Average Price Target

$4.40

▲(780.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.508,0.9304615384615385,1.352923076923077,1.7753846153846153,2.197846153846154,2.6203076923076924,3.0427692307692307,3.465230769230769,3.8876923076923076,4.310153846153846,4.732615384615385,5.155076923076923,5.577538461538461,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.508,0.8073846153846154,1.1067692307692307,1.4061538461538463,1.7055384615384617,2.004923076923077,2.3043076923076926,2.6036923076923078,2.9030769230769233,3.202461538461539,3.501846153846154,3.8012307692307696,4.100615384615385,{"y":4.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.508,0.6843076923076923,0.8606153846153846,1.036923076923077,1.2132307692307691,1.3895384615384616,1.5658461538461539,1.7421538461538462,1.9184615384615384,2.0947692307692307,2.271076923076923,2.4473846153846153,2.6236923076923078,{"y":2.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.35,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.631,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.89,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.508,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >